VALN - Valneva reports Q3 results; reaffirms FY22 guidance

• Valneva press release ( NASDAQ: VALN ): Q3 Cash and cash equivalents of €261.0M at the end of September 2022
• Revenue of €249.9M (+258.0% Y/Y).
• Valneva reiterates expected total revenues of €340 million to €360 million.
• Product sales of the Company’s travel vaccines are still expected to reach €70 million to €80 million despite supply challenges and COVID-19 product sales are expected to reach €30 million to €40 million. Other Revenues are expected to reach approximately €240 million.
• Valneva now expects lower R&D expenses of €95 million to €110 million compared to the €120 million to €135 million previously communicated.

For further details see: